Advertisement

Role of aspirin in tuberculous meningitis: A randomized open label placebo controlled trial

Published:April 26, 2010DOI:https://doi.org/10.1016/j.jns.2010.03.025

      Abstract

      Objective

      To evaluate the efficacy and safety of aspirin in preventing stroke and mortality in tuberculous meningitis (TBM).

      Methods

      Patients with TBM diagnosed on the basis of clinical, MRI and cerebrospinal fluid (CSF) criteria were randomized into aspirin 150 mg daily or placebo. All the patients received four drug antitubercular treatment- RHZE (rifampicin, isoniazide, pyrazinamide and ethambutol) with or without corticosteroid. The primary endpoint was MRI proven stroke at 3 months and secondary end points were mortality and functional outcome assessed by Barthel Index score at 3 months. The adverse drug reactions were also analyzed.

      Results

      118 TBM patients were randomized into aspirin and placebo groups. The baseline demographic, clinical (severity of meningitis, MRI and CSF changes) were not significantly different between the two groups. 19 (16.1%) patients lost from follow up. 21 (33.3%) patients developed stroke after randomization which was insignificantly lesser in aspirin (24.2%) compared to the placebo group (43.3%; OR 0.42, 95%CI 0.12-1.39). Aspirin resulted in absolute risk reduction of stroke in 19.1% and significant reduction in mortality compared to placebo (21.7% Vs 43.4%, P=0.02). On binary logistic regression analysis, the age (OR 1.09, CI 1.03-1.14, P=0.001) was the only independent risk factor of stroke and aspirin was significantly related to survival (OR 3.17, 95% CI 1.21-8.31). Aspirin was well tolerated and was not withdrawn in any patient because of side effects.

      Interpretation

      Aspirin resulted in insignificantly lesser strokes and significantly reduced 3 month mortality in patients with TBM.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. www.who.int/tb//publications/tb_global_facts_september2005_enpdf.

        • Dalal P.M.
        Obsevations on the involvement of cerebral vessels in tuberculous meningitis in adults.
        in: Goldstein M. Advances in Neurology. Vol. 25. Raven Press, New York1979: 149-159
        • Lindsey L.
        • Scholtz C.L.
        Recent presentation of neurological tuberculosis.
        J Royal Soc Med. 1978; 71: 223-227
        • Dastur D.K.
        • Lalitha V.S.
        • Udani P.M.
        • Parekh U.
        The brain and meninges in tuberculous meningitis-gross pathology in 100 cases and pathogenesis.
        Neurol India. 1970; 18: 86-100
        • Bullock M.R.
        • Welchman J.M.
        Diagnostic and prognostic features of tuberculous meningitis on CT scanning.
        J Neurol Neurosurg Psychiatr. 1982; 45: 1098-1101
        • Kingsley D.P.
        • Hendrickse W.A.
        • Kendall B.E.
        • Swash M.
        • Singh V.J.
        Tuberculous meningitis: role of CT in management and prognosis.
        J Neurol Neurosurg Psychiatr. 1987; 50: 30-36
        • Gupta R.K.
        • Gupta S.
        • Singh D.
        • Sharma B.
        • Kohli A.
        Gujral RB.
        Neuroradiology. 1994; 36: 87-92
        • Kalita J.
        • Nair P.P.
        • Misra U.K.
        Predictors of stroke and its significance in the outcome of tuberculous meningitis.
        J Stroke Cerebrovasc Dis. 2009; 18: 251-258
        • Andronikou S.
        • Wilmshurst J.
        • Hatherill M.
        • VanToorn R.
        Distribution of brain infarction in children with tuberculous meningitis and correlation with outcome score at 6 months.
        Pediatr Radiol. 2006; 36: 1289-1294
        • Misra U.K.
        • Kalita J.
        • Srivastava M.
        • Mandal S.K.
        Prognosis of tuberculous meningitis: a multivariate analysis.
        J Neurol Sci. 1996; 137: 57-61
        • Chan K.H.
        • Cheung R.T.
        • Lee R.
        • Mak W.
        • Ho S.L.
        Cerebral infarcts complicating tuberculous meningitis.
        Cerebrovasc Dis. 2005; 19: 391-395
        • Kalita J.
        • Misra U.K.
        • Ranjan P.
        Predictors of long-term neurological sequelae of tuberculous meningitis: a multivariate analysis.
        Eur J Neurol. 2007; 14: 33-37
        • Thwaites G.E.
        • Nguyen D.B.
        • Nguyen H.D.
        • Hoang T.Q.
        • Do T.T.
        • Nguyen T.C.
        • et al.
        Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.
        N Engl J Med. 2004; 351: 1741-1751
        • Thwaites G.E.
        • Macmullen-Price J.
        • Tran T.H.
        • Pham P.M.
        • Nguyen T.D.
        • Simmons C.P.
        • et al.
        Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuberculous meningitis: an observational study.
        Lancet Neurol. 2007; 6: 230-236
        • Schoeman J.
        • Mansvelt E.
        • Springer P.
        • van Rensburg A.J.
        • Carlini S.
        • Fourie E.
        Coagulant and fibrinolytic status in tuberculous meningitis.
        Pediatr Infect Dis J. 2007; 26: 428-431
        • Bousser M.G.
        Antithrombotic agents in the prevention of ischemic stroke.
        Cerebrovasc Dis. 2009; 27: S12-S19
        • Hovens M.M.
        • Snoep J.D.
        • Groeneveld Y.
        • Frölich M.
        • Tamsma J.T.
        • Huisman M.V.
        Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial.
        Diabetes Obes Metab. 2008; 10: 668-674
        • Ibáñez-Hernández M.G.
        • Macías-Islas M.A.
        • Zavalza-Gómez A.B.
        • Pacheco-Moisés F.P.
        • Ortiz G.G.
        The effect of ibuprofen and acetylsalicylic acid on cognitive impairment, total antioxidant power and isoprostane serum.
        Gac Med Mex. 2008; 144: 497-502
        • Patrono C.
        Efficacy and safety of aspirin in the long-term management of atherothrombosis.
        Haematologica. 2001; 86S2: 19-21
        • Misra U.K.
        • Kalita J.
        • Roy A.K.
        • Mandal S.K.
        • Srivastava M.
        Role of clinical, radiological, and neurophysiological changes in predicting the outcome of tuberculous meningitis: a multivariable analysis.
        J Neurol Neurosurg Psychiatr. 2000; 68: 300-303
        • Poltera A.A.
        Thrombogenic intracranial vasculitis in tuberculous meningitis. A 20 year "post mortem" survey.
        Acta Neurol Belg. 1977; 77: 12-24
        • Prasad K.
        • Singh M.B.
        Corticosteroids for managing tuberculous meningitis.
        Cochrane Database Syst Rev. 2008; 1: CD002244
        • Nesher G.
        • Berkun Y.
        • Mates M.
        • Baras M.
        • Rubinow A.
        • Sonnenblick M.
        Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis.
        Arthritis Rheum. 2004; 50: 1332-1337
        • Hereng T.
        • Lambert M.
        • Hachulla E.
        • Samor M.
        • Dubucquoi S.
        • Caron C.
        • et al.
        Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients.
        Lupus. 2008; 17: 11-15